Palo Alto Research Center Inc.

Microchips, Inc.

Massachusetts Institute of Technology

Gyroscope Therapeutics Limited

Xerox Corporation

Boston Scientific Scimed, Inc.

The Charles Stark Draper Laboratory, Inc.

Orbit Biomedical Limited

Palo Alto Research Institute Incorporated

Scott Albert Uhland

Eric Peeters

John T Santini, Jr

Norman F Sheppard, Jr

Benjamin F Polito

John M Maloney

Michael John Cima

Stephen Jack Herman

Ramkumar Abhishek

Philipp Helmut Schmaelzle

David Mathew Johnson

Martin Sheridan

Felicia Linn

Timothy J Curley

Joerg Martini

Robert Thomas Krivacic

Jonathan Robert Coppeta

Dennis Ausiello

Zouhair Sbiaa

Francisco Eduardo Torres

Barry Y Yomtov

Robert Samuel Langer

Daniel W Price

Peter Kiesel

Eugene Michael Chow

Noble Marshall Johnson

Thomas Edward Meyer

Brendan J Oberkircher

Michael F Keane

Isaac John Khan

Bryan Thomas Preas

Benjamin L Ko

Clinton W Denlinger

Daniel James Prenger

James G Lee

Mark C Tsai

Charles E Hutchinson

Geoffrey King

James H Prescott

Denis P Turner

Hussain Fatakdawala

John T Santini

Norman F Sheppard

Emanuel Michael Sachs

Serena H Wong

Barry Mitchell Yomtov

Michael I Recht

Stanley R Shanfield

Livia M Racz

Douglas W White

James G Serdy

Douglas Snell

Christina M Feakes

Michael Caradonna

Seth M Davis

Nolan T Flynn

Rebecca S Shawgo

Patrick C Saxton

Jason Grau

Jooho Moon

Mark A Staples

Michael A Caradonna

Devices, systems, and methods for delivering fluid are provided. Devices include a housing configured for intravaginal deployment and retention, at least one reservoir configured to contain a fluid, and a fluid dispensing mechanism configured to dispense the fluid past the cervix and to the uterus of the subject. Methods include intravaginally deploying and retaining a device in the subject, and dispensing the fluid from the device such that the fluid is driven past the cervix to the uterus of the subject.

Implantable fluid delivery devices, systems, and methods

An apparatus includes a pad assembly, an injector assembly, an injector driver, and a fluid source. The pad assembly is sized and configured to be placed on a forehead of a patient. The injector assembly includes a body, a flexible cannula, and a needle. The body is configured to be removably secured to the pad assembly. The cannula is sized to be inserted through an incision in an eye of a patient. The needle is slidably disposed in the cannula. The injector driver is operable to drive the needle longitudinally relative to the flexible cannula. The fluid source assembly is in fluid communication with the needle.

Injection device for subretinal delivery of therapeutic agent

Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intralumenal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

Transmucosal drug delivery device and method including chemical permeation enhancers

Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Devices and methods for intraluminal retention and drug delivery

A system for use with a drug delivery device includes a sensor unit and a deactivation unit operatively coupled to an output of the sensor unit and to a drug-retaining region of the drug delivery device, wherein the drug-retaining region contains a drug. The sensor unit is configured to detect a characteristic of a local environment and generate an output corresponding to a value of the detected characteristic. The deactivation unit is configured to render the drug ineffective when the output of the sensor unit satisfies a predetermined condition.

Sensor system for drug delivery device, drug delivery device having the same and method of using the same

Devices, systems, and methods for detecting estrus in subjects are provided. Devices include a housing configured for intravaginal/intrauterine deployment and retention and a sensor disposed in or on the housing, and are configured to use condition information sensed by the sensor to determine an estrus condition of the subject. Methods include deploying a device in the subject, sensing the condition information, and determining an estrus condition using the condition information. Systems include a device configured to communicate with a base station and/or with other implanted devices, which are located within a reception radius thereof, regarding the determined estrus condition.

Implantable estrus detection devices, systems, and methods

Approaches for determining the delivery success of a particle, such as a drug particle, are disclosed. A system for monitoring delivery of particles to biological tissue includes a volume, an optical component, a detector, and an analyzer. The volume comprises a space through which a particle can pass in a desired direction. The optical component is configured to provide a measurement light. The detector is positioned to detect light emanating from the particle in response to the measurement light. The detected light is modulated as the particle moves along a detection axis. The detector is configured to generate a time-varying signal in response to the detected light. The analyzer is configured to receive the time-varying signal and determine a delivery success of the particle into a biological tissue based upon characteristics of the time-varying signal.

Monitor for particle injector

Devices and methods are provided for drug delivery. The device may include a housing having a first compartment containing a drug in a dry, solid form, a second compartment containing a liquid carrier for the drug, and an expansion member located within or adjacent to the first or second compartment. The second compartment may be fluidly connectable to the first compartment by a rupturable barrier or mechanical valve. The device may also include an actuation system configured to expand the expansion member to rupture the rupturable barrier or open the mechanical valve and permit the liquid carrier to flow into the first compartment and mix with the drug to form a reconstituted drug solution.

Drug reconstitution and delivery device and methods

Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Multiple reservoir drug delivery device and methods

Growing community of inventors

San Jose, CA, United States of America

Scott Albert Uhland